At KYAN, we figured out how to apply complex system analytics to biomedical applications in a highly efficient and effective manner.
About KYAN Therapeutics
KYAN Therapeutics is a clinical-stage AI biotechnology company that utilizes proprietary technology to transform the way patients are treated and how therapies are developed. Our clinically-validated platforms revolutionize drug development by de-risking and dramatically accelerating the process at a fraction of the cost of traditional models.
Our platform integrates proprietary arrays, automated experimentation and AI to drive combination therapy development, media culturing, clinical stratification and dosage recommendation.
We drive the development of optimized combination therapies with existing lead molecules/compounds or INDs. Novel combinations are created more efficiently and effectively, at a fraction of the cost.
We are able to quantifiably and objectively optimize media conditions, by identifying critical components at the right ratios to maximize desired bioprocesses and/or cell culture growth with lower expenditures.
As a pre-clinical screening tool, our platform can investigate and explore patient response through ex vivo analysis, to enhance clinical trials with informed patient stratification and subpopulation grouping.
Drug Dose Recommendation
The right drugs, given at the wrong doses can result in ineffective treatment. KYAN reframes the dosing paradigm to determine dosages that can maximize efficacy and minimize toxicity simultaneously.
Read about KYAN's recent developments below.
KYAN is staffed by team members who have decades of combined research and industry experience, with a singular mission to revolutionize the way patients are treated and therapies are developed.
Reach out to us now if you have interesting studies you would like to work with KYAN on or just to say hi!
Contact Us Now
NUS Enterprise at 83 Science Park Drive, The Curie, #02-03/04, S118258
+65 9730 2672